Tafenoquine featured this year as a key innovation in a UHC special report.
About the P. vivax information hub
Video on life-changing treatment to cure relapsing P. vivax malaria.
The Malaria in Pregnancy (MiP) Library now available on WWARN.
About 8.5 million people are at risk of malaria in Nepal. Despite this progress, there was a 20% increase from 2016 to 2017.
In this study, the prevalence and distribution of G6PD mutations were investigated across Ethiopia with the goal to provide additional information relevant to the use of primaquine in malaria treatment.
This tool assesses the cost-effectiveness of using G6PD RDTs prior to the administration of primaquine.
The vivax after falciparum Study Group was formed in March 2018, with an invitation to interested researchers with relevant data sets.
This is an APMEN health Care facility & community assessment to determine populations at risk of malaria and primaquine-induced haemolysis.
This trial is investigating the impact of a short course radical cure of P. vivax in Nepal - a randomized controlled trial – pilot study.
This study is investigate risk reduction of P. vivax after falciparum infections in co-endemic areas - a randomized controlled trial (PRIMA).
Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.